Kyverna Therapeutics Inc (KYTX) Stock Price, Quote & News

Company Profile

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; a...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 925 2492

Website: kyvernatx.com

Address:

5980 Horton Street, Suite 550, Emeryville, United States

FelixH86 Dec. 24 at 7:14 PM

$KYTX

0 · Reply

Madmortigan Dec. 24 at 3:48 PM

$KYTX So any of you have target prices or just going long?

2 · Reply

Th3M4skedSt0nker Dec. 24 at 3:42 PM

$KYTX all big players in the cell therapy space like $AZN $GILD $AMGN $VRTX will have noticed these life changing results and have their M&A analysts running the numbers up and down right now to evaluate next steps in 2026. A merry Christmas to everyone here. Let's do some good with our investments here on this holy day 🎄🎅💲 https://kyvernatx.com/education-events/educational-videos/

1 · Reply

Dirk1969 Dec. 24 at 3:32 PM

$KYTX At 2,000 viewers, the current stock price is at least $20.✅📈

0 · Reply

kubota2323 Dec. 24 at 3:31 PM

$KYTX adding $AVIR now . Very Bullish on both

0 · Reply

Dirk1969 Dec. 24 at 3:26 PM

$KYTX ✅📈 https://www.fiercebiotech.com/biotech/kyverna-gains-clear-view-first-car-t-approval-autoimmune-disease-after-truly-remarkable-sps

0 · Reply

Madmortigan Dec. 24 at 3:13 PM

$KYTX slow and steady ftw

0 · Reply

kellymone2 Dec. 24 at 2:41 PM

$KYTX got in @ 8,92$ Wish me luck 🤞

1 · Reply

kubota2323 Dec. 24 at 8:37 AM

$KYTX https://kyvernatx.com/education-events/educational-videos/

0 · Reply

BioTechHealthX Dec. 24 at 5:09 AM

$KYTX Kyverna Therapeutics Inc (NASDAQ:KYTX) raised approximately $100 million to accelerate clinical trials for its lead CAR T therapy, strengthening its balance sheet and extending development runway. https://biotechhealthx.com/biotech-news/why-investors-are-watching-kyverna-therapeutics-kytx-after-its-100m-capital-raise/

0 · Reply

Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies

Dec 17, 2025, 11:59 AM EST - 8 days ago

Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript

Dec 17, 2025, 9:24 AM EST - 8 days ago

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

Dec 16, 2025, 3:46 PM EST - 9 days ago

Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing

Dec 16, 2025, 8:06 AM EST - 9 days ago

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

LWLG

Dec 15, 2025, 4:01 PM EST - 10 days ago

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

Dec 15, 2025, 12:06 PM EST - 10 days ago

Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome

Dec 15, 2025, 6:42 AM EST - 10 days ago

Kyverna's cell therapy meets main goal of mid-stage study

Dec 15, 2025, 6:30 AM EST - 10 days ago

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Dec 14, 2025, 2:30 PM EST - 11 days ago

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Dec 8, 2025, 9:00 AM EST - 17 days ago

Stock Picks From Seeking Alpha's November 2025 New Analysts

ABEV CEG CEPU EAT GLXY GT KOF

Nov 14, 2025, 2:24 AM EST - 5 weeks ago

Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential

Nov 12, 2025, 4:05 PM EST - 6 weeks ago

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 6 weeks ago

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 3, 2025, 8:00 AM EST - 7 weeks ago

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Oct 29, 2025, 6:30 AM EDT - 2 months ago

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Oct 25, 2025, 11:00 AM EDT - 2 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

Oct 22, 2025, 8:00 AM EDT - 2 months ago

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

Sep 24, 2025, 9:05 AM EDT - 3 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Sep 15, 2025, 1:02 PM EDT - 3 months ago

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Aug 28, 2025, 8:00 AM EDT - 4 months ago

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Aug 25, 2025, 4:02 PM EDT - 4 months ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Aug 20, 2025, 3:29 PM EDT - 4 months ago

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

Aug 12, 2025, 4:02 PM EDT - 4 months ago

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 8:30 AM EDT - 5 months ago

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

May 28, 2025, 4:02 PM EDT - 7 months ago

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

May 27, 2025, 3:42 PM EDT - 7 months ago

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

May 13, 2025, 4:02 PM EDT - 8 months ago

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Mar 27, 2025, 4:02 PM EDT - 9 months ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 21, 2025, 11:29 AM EDT - 9 months ago

Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025

Mar 3, 2025, 4:05 PM EST - 10 months ago

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Feb 7, 2025, 11:42 AM EST - 11 months ago

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Feb 6, 2025, 1:51 PM EST - 11 months ago

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

Feb 5, 2025, 11:54 AM EST - 11 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics

Feb 4, 2025, 3:51 AM EST - 11 months ago

Final Deadline for the Kyverna Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - KYTX

FelixH86 Dec. 24 at 7:14 PM

$KYTX

0 · Reply

Madmortigan Dec. 24 at 3:48 PM

$KYTX So any of you have target prices or just going long?

2 · Reply

Th3M4skedSt0nker Dec. 24 at 3:42 PM

1 · Reply

Dirk1969 Dec. 24 at 3:32 PM

$KYTX At 2,000 viewers, the current stock price is at least $20.✅📈

0 · Reply

kubota2323 Dec. 24 at 3:31 PM

$KYTX adding $AVIR now . Very Bullish on both

0 · Reply

Dirk1969 Dec. 24 at 3:26 PM

$KYTX ✅📈 https://www.fiercebiotech.com/biotech/kyverna-gains-clear-view-first-car-t-approval-autoimmune-disease-after-truly-remarkable-sps

0 · Reply

Madmortigan Dec. 24 at 3:13 PM

$KYTX slow and steady ftw

0 · Reply

kellymone2 Dec. 24 at 2:41 PM

$KYTX got in @ 8,92$ Wish me luck 🤞

1 · Reply

kubota2323 Dec. 24 at 8:37 AM

$KYTX https://kyvernatx.com/education-events/educational-videos/

0 · Reply

BioTechHealthX Dec. 24 at 5:09 AM

0 · Reply

FelixH86 Dec. 23 at 10:21 PM

$KYTX

0 · Reply

RunnerSignals Dec. 23 at 9:15 PM

Market Warriors Bounce Back! $RZLT $NUAI $HUMA $KYTX $AESI started down but closed up strong

0 · Reply

FelixH86 Dec. 23 at 9:13 PM

$KYTX

0 · Reply

Madmortigan Dec. 23 at 7:47 PM

$KYTX HALT!

1 · Reply

kubota2323 Dec. 23 at 6:47 PM

$KYTX be prepared for low volumes haft day trading tomorrow. The scumbag mm will be all over this.

0 · Reply

Dirk1969 Dec. 23 at 6:24 PM

$KYTX ✅📈 https://www.tipranks.com/news/insider-trading/twin-insider-buys-signal-major-confidence-in-kyverna-therapeutics-insider-trading

0 · Reply

Mag7bull Dec. 23 at 6:08 PM

$KYTX Price target ranges from 20 to 34 and it is still below 9 so damn cheap and good one

0 · Reply

Dirk1969 Dec. 23 at 6:05 PM

$KYTX ✅📈 still a significant discount compared to the stock market introduction Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering February 7, 2024 EMERYVILLE, Calif., Feb. 7, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the pricing of its upsized initial public offering of 14,500,000 shares of its common stock at an initial public offering price of $22.00 per share.

0 · Reply

Madmortigan Dec. 23 at 5:58 PM

$KYTX close over 9?

0 · Reply

moonbagbilly Dec. 23 at 5:50 PM

$KYTX

0 · Reply

Dirk1969 Dec. 23 at 5:44 PM

$KYTX I've been reading more and researching this company, 2026 is going to be amazing. Sold everything and I am now fully in here ✅📈

1 · Reply

kubota2323 Dec. 23 at 5:35 PM

$KYTX https://www.nasdaq.com/articles/kyverna-therapeutics-kytx-price-target-increased-1168-2876

1 · Reply

Market Cap	393.73M
Revenue (ttm)	0.00
Net Income (ttm)	-127.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	860,000
Avg Vol	1,540,832
Day's Range	N/A - N/A
Shares Out	43.80M
Stochastic %K	34%
Beta	3.66
Analysts	Strong Sell
Price Target	$28.20